Aprea Therapeutics (NASDAQ:APRE – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $0.15 million for the quarter.
Aprea Therapeutics Stock Performance
APRE stock opened at $2.34 on Tuesday. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $6.88. The company’s 50-day simple moving average is $3.30 and its 200 day simple moving average is $3.30. The company has a market capitalization of $12.72 million, a PE ratio of -0.83 and a beta of 0.82.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a report on Wednesday, January 15th.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.
Featured Stories
- Five stocks we like better than Aprea Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- Can TikTok Stock Picks Really Make You Rich?
- Health Care Stocks Explained: Why You Might Want to Invest
- The “Quality” Rotation: Back to Basics Investing
- What is the FTSE 100 index?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
